A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial

BACKGROUND: Sorafenib is an oral multikinase inhibitor with antiangiogenic/antiproliferative activity. A randomized phase 2b screening trial in human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer demonstrated a significant improvement in progression-free survival (PFS) wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Baselga, José, Costa, Frederico, Gomez, Henry, Hudis, Clifford A, Rapoport, Bernardo, Roche, Henri, Schwartzberg, Lee S, Petrenciuc, Oana, Shan, Minghua, Gradishar, William J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3724697/
https://www.ncbi.nlm.nih.gov/pubmed/23876062
http://dx.doi.org/10.1186/1745-6215-14-228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3724697/
https://www.ncbi.nlm.nih.gov/pubmed/23876062
http://dx.doi.org/10.1186/1745-6215-14-228

Ejemplares similares